A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Completed · Phase 2 · NCT04634409
Conditions: COVID-19
At a glance
- Research payments reported, 2025
- $60,675
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 1,755
About the trial
- Sponsor
- Eli Lilly and Company (with AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd., GlaxoSmithKline, Vir Biotechnology, Inc.)
- Tested
- Bamlanivimab (drug), Etesevimab (drug), Placebo (drug), VIR-7831 (drug), Bebtelovimab (drug)
- Dates
- Started 2020-10-29; completion 2021-10-18
- Results posted
- Yes
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
From ClinicalTrials.gov, last updated 2022-07-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $60,675 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nader Sobh, D.O. Family Medicine · Los Angeles, CA
- James P. Krainson, M.D.F.C.C.P. Pulmonology · Miami, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Smart Cures Clinical Research LLC $56,925
- Clinical Site PArtners LLC $3,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.